Compare BGY & LENZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BGY | LENZ |
|---|---|---|
| Founded | 2007 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 515.6M | 609.5M |
| IPO Year | N/A | 2021 |
| Metric | BGY | LENZ |
|---|---|---|
| Price | $5.40 | $9.28 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $45.60 |
| AVG Volume (30 Days) | 410.2K | ★ 1.0M |
| Earning Date | 01-01-0001 | 03-24-2026 |
| Dividend Yield | ★ 7.41% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $19,088,000.00 |
| Revenue This Year | N/A | $162.79 |
| Revenue Next Year | N/A | $170.32 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.67 | $8.25 |
| 52 Week High | $6.23 | $50.19 |
| Indicator | BGY | LENZ |
|---|---|---|
| Relative Strength Index (RSI) | 38.32 | 36.82 |
| Support Level | N/A | N/A |
| Resistance Level | $5.86 | $12.70 |
| Average True Range (ATR) | 0.09 | 0.87 |
| MACD | -0.01 | -0.15 |
| Stochastic Oscillator | 35.45 | 24.61 |
Blackrock Enhanced International Dividend Trust is a diversified closed-end management investment company. Its primary investment objective is to provide current income and current gains, with a secondary objective of long-term capital appreciation. The Trust invests the majority of its net assets in dividend-paying equity securities issued by non-U.S. companies of any market capitalization, with a key focus on securities of large capitalization companies. It invests directly in such securities or synthetically through the use of derivatives.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.